AU2019262220A8 - Methods of diagnosing and treating based on site-specific tau phosphorylation - Google Patents

Methods of diagnosing and treating based on site-specific tau phosphorylation Download PDF

Info

Publication number
AU2019262220A8
AU2019262220A8 AU2019262220A AU2019262220A AU2019262220A8 AU 2019262220 A8 AU2019262220 A8 AU 2019262220A8 AU 2019262220 A AU2019262220 A AU 2019262220A AU 2019262220 A AU2019262220 A AU 2019262220A AU 2019262220 A8 AU2019262220 A8 AU 2019262220A8
Authority
AU
Australia
Prior art keywords
tau phosphorylation
diagnosing
site
methods
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019262220A
Other versions
AU2019262220A1 (en
Inventor
Nicolas BARTHELEMY
Randall John Bateman
Eric MCDADE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of AU2019262220A1 publication Critical patent/AU2019262220A1/en
Publication of AU2019262220A8 publication Critical patent/AU2019262220A8/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)

Abstract

The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.
AU2019262220A 2018-05-03 2019-05-03 Methods of diagnosing and treating based on site-specific tau phosphorylation Pending AU2019262220A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862666504P 2018-05-03 2018-05-03
US201862666509P 2018-05-03 2018-05-03
US62/666,509 2018-05-03
US62/666,504 2018-05-03
PCT/US2019/030725 WO2019213612A1 (en) 2018-05-03 2019-05-03 Methods of diagnosing and treating based on site-specific tau phosphorylation

Publications (2)

Publication Number Publication Date
AU2019262220A1 AU2019262220A1 (en) 2020-11-12
AU2019262220A8 true AU2019262220A8 (en) 2020-12-10

Family

ID=68386729

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019262220A Pending AU2019262220A1 (en) 2018-05-03 2019-05-03 Methods of diagnosing and treating based on site-specific tau phosphorylation

Country Status (11)

Country Link
EP (1) EP3788062A4 (en)
JP (1) JP7301394B2 (en)
KR (1) KR20210004996A (en)
CN (1) CN112166117A (en)
AU (1) AU2019262220A1 (en)
BR (1) BR112020021782A2 (en)
CA (1) CA3097667A1 (en)
MX (1) MX2020011458A (en)
SG (1) SG11202010094TA (en)
WO (1) WO2019213612A1 (en)
ZA (1) ZA202006348B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102502356B1 (en) 2014-09-30 2023-02-21 워싱턴 유니버시티 Tau kinetic measurements
EP4013772A4 (en) * 2019-08-13 2024-06-05 Washington University Methods to detect mtbr tau isoforms and use thereof
JP2022547209A (en) * 2019-09-10 2022-11-10 ワシントン・ユニバーシティ A Blood-Based Assay for Diagnosis and Treatment Based on Site-Specific Tau Phosphorylation
US20230132508A1 (en) * 2020-04-01 2023-05-04 Genentech Inc. Uses of Tau Phosphosites as Biomarkers for Alzheimer's Disease
JP2023551542A (en) 2020-11-30 2023-12-08 エニグマ バイオインテリジェンス，インコーポレイテッド Non-invasive assessment of Alzheimer's disease
CN112763636B (en) * 2020-12-07 2022-04-19 佛山汉腾生物科技有限公司 Peptide map analysis method
CA3213085A1 (en) * 2021-03-31 2022-10-06 Chihiro Sato Csf phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies
WO2023288336A1 (en) * 2021-07-16 2023-01-19 Washington University Methods of detecting pentasaccharides and treatment and monitoring of lysosomal storage disease
WO2023068173A1 (en) * 2021-10-18 2023-04-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 BIOMARKER FOR EVALUATING INTRACEREBRAL AMYLOID-β ACCUMULATION
KR20240002809A (en) * 2022-06-30 2024-01-08 광주과학기술원 Method for Early Diagnosis and Staging of Alzheimer's Disease and Screening Cerebral Amyloid Deposition Using Phosphorylated Peptide Derived from Tau Protein
KR20240002810A (en) * 2022-06-30 2024-01-08 광주과학기술원 Method for Early Diagnosis and Staging of Alzheimer's Disease and Screening Cerebral Amyloid Deposition Using Phosphorylated Peptide Derived from Alzheimer's Disease Related Protein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101124247B (en) * 2004-07-30 2013-07-31 礼纳特神经系统科学公司 Antibodies directed against amyloid-beta peptide and uses thereof
US20080220449A1 (en) * 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
WO2010011506A2 (en) * 2008-07-23 2010-01-28 The Washington University Risk factors and a therapeutic target for neurodegenerative disorders
FR2963791B1 (en) 2010-08-11 2012-09-21 Assist Publ Hopitaux De Paris METHOD OF DIAGNOSING NEURODEGENERATIVE DISEASES
DK2758433T3 (en) * 2011-09-19 2018-01-15 Axon Neuroscience Se PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY OF ALZHEIMER'S DISEASE
EP2764022B9 (en) * 2011-10-07 2017-02-22 AC Immune S.A. Phosphospecific antibodies recognising tau
EP2787349A1 (en) * 2013-04-03 2014-10-08 Affiris AG Method for detecting proteinopathy-specific antibodies in a biological sample
KR102384115B1 (en) 2013-10-24 2022-04-07 나노소믹스 인코포레이티드 Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders
SG11201703237VA (en) * 2014-11-19 2017-06-29 Axon Neuroscience Se Humanized tau antibodies in alzheimer's disease
US11698378B2 (en) * 2015-09-25 2023-07-11 Children's Medical Center Corporation Methods and compositions for tauopathy diagnosis and treatment

Also Published As

Publication number Publication date
MX2020011458A (en) 2020-12-07
AU2019262220A1 (en) 2020-11-12
CA3097667A1 (en) 2019-11-07
CN112166117A (en) 2021-01-01
JP2021523357A (en) 2021-09-02
EP3788062A1 (en) 2021-03-10
KR20210004996A (en) 2021-01-13
BR112020021782A2 (en) 2021-02-23
SG11202010094TA (en) 2020-11-27
EP3788062A4 (en) 2022-02-16
WO2019213612A1 (en) 2019-11-07
ZA202006348B (en) 2022-01-26
JP7301394B2 (en) 2023-07-03

Similar Documents

Publication Publication Date Title
AU2019262220A8 (en) Methods of diagnosing and treating based on site-specific tau phosphorylation
WO2018112446A3 (en) Use of apoe4 motif-mediated genes for diagnosis and treatment of alzheimer's disease
CY1118566T1 (en) DIAGNOSIS USING INTERFERENCE TYPE 1
ZA202201230B (en) Biomarkers and treatments of alzheimer’s disease and mild cognitive impairment
WO2015153864A3 (en) Methods for treating inflammatory conditions
MX2022002880A (en) Blood-based assay for diagnosing and treating based on site-specific tau phosphorylation.
MX2021008797A (en) Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors.
WO2019236750A3 (en) Targeted treatment of autism spectrum disorder and other neurological or psychiatric disorders
MX2023007587A (en) Treatment of liver diseases with cell death inducing dffa like effector b (cideb) inhibitors.
IL312649A (en) System and method for diagnosing and treating biological rhythm disorders
WO2020077341A8 (en) Methods and compositions for identifying and treating subjects at risk for poor car t cell therapy response
EP3852774A4 (en) Methods for diagnosis and treatment of type 1 diabetes
EP3740761A4 (en) Companion diagnostic for nsaids and donepezil for treating specific subpopulations of patients suffering from alzheimer's disease
WO2020209988A3 (en) Diverse marker panel for ptsd diagnosis and treatment
MX2021010467A (en) Biomarkers for joint ailments and uses thereof.
WO2022104136A3 (en) Methods and compositions for tauopathy diagnosis and treatment
EP4030995A4 (en) Methods for diagnosing and treating neural diseases
MX2023015183A (en) Biomarkers for alzheimer's disease treatment.
BR112021025504A2 (en) Methods to treat neurodegenerative disorders
EA202290037A1 (en) METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
WO2019070813A3 (en) Use of peptides as biomarkers in the diagnosis, confirmation and treatment of a neurological disorder
Völker et al. An overview of the quality of life in patients with schizophrenia
WO2023039175A3 (en) Predictors of achromatopsia treatment efficacy
WO2024129443A3 (en) Diagnosing concomitant fibromyalgia and lupus and determining treatment efficacy
Valiulis et al. In search of optimal site for 10 Hz rTMS depression treatment: a clinical and physiological comparison

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 34 , NO 45 , PAGE(S) 6450 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME WASHINGTON UNIVERSITY, APPLICATION NO. 2019262220, UNDER INID (72) CORRECT THE CO-INVENTOR TO BATEMAN, RANDALL JOHN